BioCentury | Apr 28, 2008
Clinical News

Neu2000KL: Phase I final data

...up to 6,000 mg of Neu2000KL were well tolerated. There were no serious adverse events. Amkor Pharma Inc....
BioCentury | Apr 3, 2008
Distillery Therapeutics

This Week in Therapeutics

...progression or prominent axonal loss in the spinal cord. Researchers did not disclose next steps. Amkor Pharma Inc.'s...
Items per page:
1 - 2 of 2
BioCentury | Apr 28, 2008
Clinical News

Neu2000KL: Phase I final data

...up to 6,000 mg of Neu2000KL were well tolerated. There were no serious adverse events. Amkor Pharma Inc....
BioCentury | Apr 3, 2008
Distillery Therapeutics

This Week in Therapeutics

...progression or prominent axonal loss in the spinal cord. Researchers did not disclose next steps. Amkor Pharma Inc.'s...
Items per page:
1 - 2 of 2